What are Regeneron's main product candidates in development and their current status?

Regeneron has four primary clinical development programs: ARCALYST™ (rilonacept) for inflammatory diseases, aflibercept (VEGF Trap) for oncology, VEGF Trap-Eye for eye diseases, and REGN88, an antibody targeting the Interleukin-6 receptor for rheumatoid arthritis. ARCALYST™ was under FDA priority review for Cryopyrin-Associated Periodic Syndromes (CAPS), aflibercept was advancing through Phase 3 trials in oncology, and VEGF Trap-Eye was in Phase 3 trials for wet age-related macular degeneration (wet AMD).

How did Regeneron's financial performance change in 2007 compared to 2006?

In 2007, Regeneron saw a significant increase in revenue to $125 million from $63.4 million in 2006, primarily due to upfront and milestone payments from collaborations. However, the company's net loss also slightly increased to $105.6 million from $102.3 million, driven by higher research and development spending of $201.6 million compared to $137.1 million in 2006.

What are the key risks and challenges facing Regeneron, as highlighted in the filing?

Regeneron faces significant risks including the high uncertainty of drug development success, the lengthy and expensive clinical trial process, the need for substantial future financing, intense competition from established pharmaceutical companies, potential delays or failures in regulatory approvals, and reliance on third-party collaborators like sanofi-aventis and Bayer HealthCare. The company also has a substantial amount of convertible debt maturing in October 2008.

What is the status of Regeneron's major collaborations?

Regeneron has key collaborations with sanofi-aventis for aflibercept (oncology) and for the development of fully human monoclonal antibodies, and with Bayer HealthCare for VEGF Trap-Eye. These collaborations involve significant funding, development cost-sharing, and potential milestone and royalty payments, indicating a strategic reliance on these partnerships for advancing its pipeline.

REGN 10-K FY2007 Annual Report — Revenue, Net Income, EPS

Summary

Regeneron Pharmaceuticals, Inc. reported a net loss of $105.6 million for the year ended December 31, 2007, a slight increase from the $102.3 million loss in 2006. The company's revenue significantly increased to $125 million in 2007, driven by substantial upfront payments and progress payments from collaborations with sanofi-aventis and Bayer HealthCare, alongside technology licensing revenue. Research and development expenses also rose to $201.6 million, reflecting increased investment in clinical programs, particularly for ARCALYST™, aflibercept, and VEGF Trap-Eye, as well as the advancement of its antibody programs. Financially, Regeneron ended 2007 with a stronger cash position, holding $846.3 million in cash, cash equivalents, and marketable securities, bolstered by significant funding from its collaborations. The company faces a substantial debt maturity in October 2008 with $200 million in convertible notes. Despite ongoing losses, the company anticipates meeting its operating needs through at least 2012, supported by its substantial cash reserves and expected collaboration funding.

Key Highlights

1Regeneron reported a net loss of $105.6 million for the year ended December 31, 2007, compared to a net loss of $102.3 million in 2006.
2Total revenues for 2007 increased significantly to $125 million, up from $63.4 million in 2006, largely due to collaboration and licensing agreements.
3Research and development expenses increased to $201.6 million in 2007, up from $137.1 million in 2006, reflecting expanded clinical development programs.
4The company ended 2007 with $846.3 million in cash, cash equivalents, and marketable securities, indicating a strong liquidity position.
5Regeneron has four clinical development programs, including late-stage programs for ARCALYST™ (rilonacept), aflibercept (VEGF Trap in oncology), and VEGF Trap-Eye (in eye diseases).
6The company has a significant debt obligation of $200 million in convertible notes maturing in October 2008.
7Regeneron relies heavily on strategic collaborations with sanofi-aventis and Bayer HealthCare for funding and development of its product candidates.

REGENERON PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2007

Summary

Key Highlights

Frequently Asked Questions